SCHEMBL1839601

SCHEMBL1839601

OCC1CCCN(c2ncc(Br)cn2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYMP P19971 2/20 0.45
KHK P50053 1/20 0.43
MAP4K4 O95819 1/20 0.43
POLB P06746 3/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
CDK8 P49336 1/20 0.40
PIK3CA P42336 2/20 0.39
MTOR P42345 2/20 0.39
GRM2 Q14416 1/20 0.39
GRM3 Q14832 1/20 0.39
PDE10A Q9Y233 1/20 0.39
CTSL P07711 1/20 0.39
CTSS P25774 1/20 0.39
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
IRAK1 P51617 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
IGF1R P08069 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24656055 0.85 KHK (0.49) TYMPKHKMAP4K4POLBHTT
SCHEMBL24184101 0.84 ACACB (0.40) GRM2GRM3PDE10AKDM4E
SCHEMBL12412546 0.81 PTGS1 (0.46) TYMPKHKMAP4K4POLBHTT
SCHEMBL11360192 0.81 PDE10A (0.48) TYMPGRM2GRM3PDE10A
SCHEMBL23246818 0.80 HDAC6 (0.50) GRM2GRM3
SCHEMBL28171500 0.78 GRM2 (0.35) POLBGRM2GRM3CTSLCTSS
SCHEMBL21135573 0.77 CDK8 (0.46) TYMPKHKMAP4K4POLBHTT
SCHEMBL1027516 0.76 CAMK1D (0.43) MAP4K4
SCHEMBL29197287 0.76 GRM2 (0.39) GRM2GRM3PDE10ACTSLCTSS
SCHEMBL29197283 0.76 GRM2 (0.39) GRM2GRM3PDE10ACTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3371196-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION UNIV MONTREAL (CA) 2021-10-27 EP disclosed
US-10329307-B2 Heterocyclic compounds as inhibitors of platelet aggregation UNIVERSITE DE MONTREAL (CA) 2019-06-25 US disclosed
US-20110166088-A1 BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2011-07-07 US disclosed
EP-2321309-A1 BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS Ranbaxy Laboratories Limited (IN) 2011-05-18 EP disclosed
WO-2009156966-A1 BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329307-B2 Heterocyclic compounds as inhibitors of platelet aggregation F12, F2, F3 TYMP 1450/4885KHK 2840/4885MAP4K4 1927/4885
US-20110166088-A1 BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS TOP2B, TOP1, POLI TYMP 75/4885KHK 332/4885MAP4K4 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.